$SGNT (Sagent Pharmaceuticals, Inc.)

$SGNT {{ '2016-02-25T18:15:43+0000' | timeago}} • Announcement

$SGNT, a specialty injectables company, said it appointed Frank Harmon as executive vice president, Global Operations. Harmon will report to Allan Oberman, the chief executive officer.

$JNJ {{ '2018-01-23T20:22:09+0000' | timeago}} • Webcast

$JNJ said its best-selling Remicade, a drug for rheumatoid arthritis, fell almost 10% in 4Q17, hurt by stiff competition from biosimilars. Meanwhile, sale of consumer health products increased over 3% during the quarter.

$JNJ {{ '2018-01-23T20:02:58+0000' | timeago}} • Webcast

$JNJ said that it has approx $16Bil in cash accumulated in foreign markets. The pharma giant added that it plans to immediately transfer $12Bil of this amount into the country, to fund its US operations and also pay debts.

$JNJ {{ '2018-01-23T13:43:35+0000' | timeago}} • Announcement

$JNJ expects sales of $80.6Bil to $81.4Bil in FY18, reflecting expected operational growth in the range of 3.5% to 4.5%. Adjusted EPS for this period is estimated to be $8.00 to $8.20.

$JNJ {{ '2018-01-23T13:40:35+0000' | timeago}} • Announcement

Pharma giant $JNJ swung to a loss of $10.7Bil, or $3.99 per share in 4Q17, driven by tax-related expenses of $13.6Bil. Excluding the one-time costs, net income grew 10% to $1.74 per share. Riding on double-digit growth in drug sales during the quarter, total revenue jumped 11.5% to $20.2Bil.

$JNJ {{ '2018-01-23T13:27:16+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphic: Q4 2017 Highlights

$GILD {{ '2018-01-18T17:34:32+0000' | timeago}} • Announcement

Kite, a $GILD company, has entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the combination of Yescarta and Pfizer's utomilumab, in patients with refractory large B-cell lymphoma. A multi-center Phase 1/2 study sponsored by Kite is expected to begin in 2018.

$MDT {{ '2018-01-16T17:16:57+0000' | timeago}} • Announcement

$MDT received FDA clearance of the Riptide Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. This is designed to retrieve thrombus (or blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke.

$MD {{ '2018-01-10T15:20:12+0000' | timeago}} • Announcement

$MD announced the acquisition of Tri-Valley Neonatal Medical Group, Inc., a private neonatology physician practice based in California. This was a cash transaction and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed.

$VRTX {{ '2018-01-10T15:15:09+0000' | timeago}} • Announcement

$VRTX said the European Commission has granted extension of the Marketing Authorization for ORKAMBI, intended for the treatment of cystic fibrosis (CF) in people with two copies of the F508del mutation, to include children ages 6 through 11. Existing reimbursement agreements in countries such as Ireland will enable rapid access to ORKAMBI.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$MRK {{ '2018-01-09T20:27:32+0000' | timeago}} • Announcement

Pharma company $MRK said the FDA has granted 'Breakthrough Therapy Designation' for Lenvima, a multiple receptor tyrosine kinase inhibitor developed by Eisai in combination with Merck's anti-PD-1 therapy Keytruda for the treatment of renal cell carcinoma. The FDA action was based on the results of a multi-center study conducted in US and Europe.

$MRK {{ '2018-01-09T18:45:44+0000' | timeago}} • Announcement

Merck today announced that it has received Breakthrough Therapy Designation from FDA for LENVIMA and KEYTRUDA. The combination therapy (LENVIMA & KEYTRUDA) is being jointly developed by Eisai and $MRK for treating patients with advanced and/or metastatic renal cell carcinoma. In 2017, approx. 63,990 new cases were estimated to have occurred in US.

$LLY {{ '2018-01-08T19:33:20+0000' | timeago}} • Announcement

$LLY join hands with consumer digital health company Livongo Health to study real world behaviors of people affected with diabetes. This collaboration is expected help the diabetic people to better manage their condition.

$MLNT {{ '2018-01-08T17:08:01+0000' | timeago}} • Announcement

$MLNT completed the acquisition of $MDCO’s infectious disease business. $MLNT also announced that $MDCO’s Mike McGuire has joined the new organization as SVP, Commercial, replacing Chief Commercial Officer, John Temperato, who left $MLNT to pursue other opportunities.

$MDCO {{ '2018-01-08T13:17:52+0000' | timeago}} • Announcement

Pharma firm $MDCO closed the sale of its infectious disease business to $MLNT for $215MM of guaranteed cash and 3.3 MM common shares of Melinta. The sale consideration also includes royalty payments of 5-25% on certain drug sales and the assumption by Melinta of all royalty, milestone and other payment obligations relating to those products.

$ACOR {{ '2018-01-08T12:56:05+0000' | timeago}} • Announcement

Bio-pharmaceuticals company $ACOR has reported net sales of $542MM for fiscal 2017. For fiscal 2018, the company expects net sales to be in the range of $330MM to $350MM. R&D and SG&A operating expenses, on an adjusted basis, is forecasted in the $270-$290MM range.

$PFE {{ '2018-01-04T13:11:11+0000' | timeago}} • Announcement

Arvinas LLC collaborates with $PFE for the discovery and development of drug candidates using Arvinas' PROTAC Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Arvinas may receive up to $830MM in upfront and potential development and commercialization milestone payments.

$MCK {{ '2018-01-03T15:10:09+0000' | timeago}} • Announcement

$MCK announced that it has completed the acquisition of RxCrossroads.

$MRK {{ '2018-01-02T20:34:14+0000' | timeago}} • Announcement

Merck announced today that Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its cancer drug KEYTRUDA for treating patients with Urothelial Carcinoma, a type of bladder cancer. This approval helps $MRK to market KEYTRUDA for 4 types of cancer in Japan. The company plans to market KEYTRUDA in partnership with Taiho Pharmaceuticals.

$ACET {{ '2018-01-02T20:11:33+0000' | timeago}} • Announcement

$ACET's finished dosage form generics subsidiary Rising Pharmaceuticals launched the first generic for Efavirenz Capsules. This is an FDA-approved generic version of the reference listed drug, Sustiva from $BMY, which in combination with other drugs is indicated for the treatment of HIV-1 infection in adults and pediatric patients.

Recent Transcripts

JNJ (Johnson & Johnson)
Tuesday, January 23 2018 - 1:30pm
MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
GHDX (Genomic Health Inc.)
Wednesday, November 8 2017 - 9:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
CBM (Cambrex Corporation.)
Tuesday, November 7 2017 - 1:30pm
MNK (Mallinckrodt Public Limited Company)
Tuesday, November 7 2017 - 1:30pm
FLXN (Flexion Therapeutics, Inc.)
Monday, November 6 2017 - 9:30pm
LCI (Lannett Company, Inc.)
Monday, November 6 2017 - 9:30pm
ACET (Aceto Corp.)
Friday, November 3 2017 - 1:00pm
GNCA (Genocea Biosciences, Inc.)
Thursday, November 2 2017 - 1:00pm
GERN (Geron Corporation)
Wednesday, November 1 2017 - 8:30pm
MD (MEDNAX, Inc.)
Wednesday, November 1 2017 - 2:00pm
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
RDY (Dr. Reddy's Laboratories Ltd.)
Tuesday, October 31 2017 - 1:00pm
ACOR (Acorda Therapeutics, Inc.)
Tuesday, October 31 2017 - 12:30pm
MRK (Merck & Co. Inc.)
Friday, October 27 2017 - 12:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, October 26 2017 - 8:30pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
MCK (McKesson Corporation)
Thursday, October 26 2017 - 12:00pm

AlphaGraphics you may like